CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells [RNA-seq]
RNA-seq (gene expression) · human · 27 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Prostate cancerThis series is part of our curated briefing on it.
- Samples
- 27 samples: 9 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cellsCell reports · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE263385_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1097251 and SRA study SRP500160. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 27 samples.
How we read this: 9 replicated groups read from 27 sample titles; they account for 27 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8190670 LNCaP CTRL sh BR1 LNCaP CTRL sh B
- GSM8190671 LNCaP CPSF1 sh1 BR1 LNCaP CPSF1 sh1 B
- GSM8190672 LNCaP CPSF1 sh2 BR1 LNCaP CPSF1 sh2 B
- GSM8190673 LNCaP CTRL sh BR2 LNCaP CTRL sh B
- GSM8190674 LNCaP CPSF1 sh1 BR2 LNCaP CPSF1 sh1 B
- GSM8190675 LNCaP CPSF1 sh2 BR2 LNCaP CPSF1 sh2 B
- GSM8190676 LNCaP CTRL sh BR3 LNCaP CTRL sh B
- GSM8190677 LNCaP CPSF1 sh1 BR3 LNCaP CPSF1 sh1 B
- GSM8190678 LNCaP CPSF1 sh2 BR3 LNCaP CPSF1 sh2 B
- GSM8190679 LNCaP95 CTRL sh BR1 LNCaP95 CTRL sh B
- GSM8190680 LNCaP95 CPSF1 sh1 BR1 LNCaP95 CPSF1 sh1 B
- GSM8190681 LNCaP95 CPSF1 sh2 BR1 LNCaP95 CPSF1 sh2 B
- GSM8190682 LNCaP95 CTRL sh BR2 LNCaP95 CTRL sh B
- GSM8190683 LNCaP95 CPSF1 sh1 BR2 LNCaP95 CPSF1 sh1 B
- GSM8190684 LNCaP95 CPSF1 sh2 BR2 LNCaP95 CPSF1 sh2 B
- GSM8190685 LNCaP95 CTRL sh BR3 LNCaP95 CTRL sh B
- GSM8190686 LNCaP95 CPSF1 sh1 BR3 LNCaP95 CPSF1 sh1 B
- GSM8190687 LNCaP95 CPSF1 sh2 BR3 LNCaP95 CPSF1 sh2 B
- GSM8190688 22Rv1 CTRL sh BR1 22Rv1 CTRL sh B
- GSM8190689 22Rv1 CPSF1 sh1 BR1 22Rv1 CPSF1 sh1 B
- GSM8190690 22Rv1 CPSF1 sh2 BR1 22Rv1 CPSF1 sh2 B
- GSM8190691 22Rv1 CTRL sh BR2 22Rv1 CTRL sh B
- GSM8190692 22Rv1 CPSF1 sh1 BR2 22Rv1 CPSF1 sh1 B
- GSM8190693 22Rv1 CPSF1 sh2 BR2 22Rv1 CPSF1 sh2 B
- GSM8190694 22Rv1 CTRL sh BR3 22Rv1 CTRL sh B
- GSM8190695 22Rv1 CPSF1 sh1 BR3 22Rv1 CPSF1 sh1 B
- GSM8190696 22Rv1 CPSF1 sh2 BR3 22Rv1 CPSF1 sh2 B
- GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
- GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
- GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
- GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares prostate
- GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
- GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
- GSE309034 Combined BET Bromodomain and DNMT Inhibition Targets Lineage Plasticity in Prostate Cancer [BETi_DNMTi_human_RNAseq] 44 samples shares inhibition, prostate
- GSE292828 Inhibition of NFAT after human uterus transplant promotes loss of tissue-resident NK cells and attendant pregnancy complications [scRNA-seq] 39 samples shares inhibition, promotes
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.